The idiopathic pulmonary fibrosis (IPF) therapy market across the US and European Union (EU) will be worth more than $1.1 billion by 2017, and pharma companies could stand to benefit handsomely if they can add to the limited knowledge of the disease, says new research.
With more than 70,000 people in the US and EU estimated to be suffering from IPF, it represents a commercially attractive patient population size with a financially appealing orphan drug status, according to the research, from GlobalData.
However, the disease – a chronic condition characterised by damage to the lung resulting from inflammation and scarring – has been overlooked by the healthcare industry until the last decade and, with no fully-effective therapies other than lung transplantation, very little is understood about its heterogeneous nature. Moreover, it has a disease course that varies greatly between affected individuals.
Read the entire article at:
For more information about Idiopathic Pulmonary Fibrosis please visit: www.ipftoday.com